...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Low-Dose Rosuvastatin Improves Arterial Stiffness in High-Risk Japanese Patients With Dyslipdemia in a Primary Prevention Group – A Comparison With Fluvastatin –
【24h】

Low-Dose Rosuvastatin Improves Arterial Stiffness in High-Risk Japanese Patients With Dyslipdemia in a Primary Prevention Group – A Comparison With Fluvastatin –

机译：低剂量瑞舒伐他汀在一级预防组中改善高危日本血脂异常患者的动脉僵硬度–与氟伐他汀的比较–

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The treatment effects of rosuvastatin on arterial stiffness were assessed and compared to those of fluvastatin in high-risk Japanese patients with dyslipidemia in a primary prevention group. Methods and Results: Patients were randomly assigned to either 2.5-5mg/day of rosuvastatin (Group A) or 20-40mg/day of fluvastatin (Group B) and followed up for 12 months. In Group A (n=38), there was a progressive reduction in brachial-ankle pulse wave velocity (baPWV) along with a decrease in the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol (L/H) ratio and high-sensitivity C-reactive protein (hsCRP), and the change in baPWV correlated significantly with that of the L/H ratio and that of hsCRP after rosuvastatin treatment. In Group B (n=37), although fluvastatin achieved a significant improvement in baPWV, L/H ratio, and hsCRP, baPWV was significantly greater than that in Group A and showed a significant correlation with that of hsCRP alone after fluvastatin treatment. In a subgroup of patients (n=26), switching from fluvastatin to rosuvastatin further improved baPWV and the L/H ratio without altering hsCRP after 12 months. Conclusions: Low-dose rosuvastatin would be more effective than fluvastatin in improving arterial stiffness in high-risk Japanese patients with dyslipidemia. The results suggest that improvement in arterial stiffness by rosuvastatin mainly depends on its strong lipid-lowering effects, whereas that by fluvastatin is strongly dependent on the pleiotropic effects, especially an anti-inflammatory action. ( Circ J 2011; 75: 2660-2667)
机译：背景：在一级预防组中，评估了瑞舒伐他汀对动脉僵硬的治疗效果，并将其与氟伐他汀的治疗效果进行了比较，并将其与高血脂异常的日本高危患者进行了比较。方法和结果：患者被随机分配为2.5-5mg /天的瑞舒伐他汀（A组）或20-40mg /天的氟伐他汀（B组），并随访12个月。在A组（n = 38）中，臂踝脉搏波速度（baPWV）逐渐降低，而低密度脂蛋白胆固醇/高密度脂蛋白胆固醇（L / H）比例和高脂蛋白胆固醇降低。瑞舒伐他汀治疗后敏感性C反应蛋白（hsCRP）和baPWV的变化与L / H比和hsCRP的变化显着相关。在B组（n = 37）中，尽管氟伐他汀在baPWV，L / H比和hsCRP方面均取得了显着改善，但baPWV显着高于A组，并且与氟伐他汀治疗后单独的hsCRP显着相关。在亚组患者中（n = 26），从氟伐他汀转为瑞舒伐他汀在12个月后进一步改善了baPWV和L / H比，而没有改变hsCRP。结论：小剂量瑞舒伐他汀在改善日本血脂异常高危患者的动脉僵硬度方面比氟伐他汀更有效。结果表明，瑞舒伐他汀对动脉僵硬度的改善主要取决于其强大的降脂作用，而氟伐他汀对动脉僵硬度的依赖性主要取决于其多效作用，尤其是抗炎作用。 （Circ J 2011; 75：2660-2667）

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号